DIAGNOSTIC_TEST
genetic polymorphism
GLP1 RA and GIP R polymorphisms will be assesed from venous blood samples
Genetic, Microbiological and Behavioral Factors in Obesity
Status
Recruiting
Phase
Not applicable
Enrollment
200
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity. 200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
Interventions
Treatment arms and agents.
DIAGNOSTIC_TEST
gut microbiome
stool samples and oral cavity swabs for gut microbiome will be collected to assess V3 and V4 of gene 16s rRNA
Timeline
From registration to results.
First posted
Jun 16, 2026
Study start
May 23, 2026
Primary completion
May 2027
Study completion
May 2028
Results posted
Not reported
Registry updated
Jun 16, 2026
Outcomes
What the study measures.
Primary outcomes
weight change
Time frame · 1 and 6 months
weight change measured in kg and as BMI
Secondary outcomes
treatment discontinuation
Time frame · up to 6 months
number of patients who discontinue treatment prematurely
adverse reactions
Time frame · up to 6 months
any adverse gastrointestinal events and complications associated with tirzepatide treatment - frequency and intensity
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion criteria * Age 18-60 years * Consent to participate in the study and providing informed written consent * Overweight or obese with a BMI \>27 Exclusion criteria * Contraindications to tirzepatide use: * Type 1 or type 2 diabetes * Pregnancy or breastfeeding * Cancer * Heart failure * Expected lack of patient compliance * Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection), * Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis * Mental illness * Alcohol dependence syndrome * Liver cirrhosis * Post-myocardial infarction or stroke
Study locations
2 registered sites.
Poland. Showing up to 24 locations stored in the fast local snapshot.
Waga Zmiany
Krakow, Poland
Luxmed sp zoo
Warsaw, Poland
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Tirzepatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.